AstraZeneca’s Tezepelumab found to significantly reduce Asthma Exacerbations
One of the global Biopharma Majors, AstraZeneca has recently announced that their Biologics License Application (BLA) for Tezepelumab has been granted Priority Review by the US FDA. This acceptance of Priority Review is for the treatment of Asthma. As per the company’s recent press release, Tezepelumab which is developed in collaboration with Amgen is the…
News Views